

Expert Forum on

LYMPHOMA

Hodgkin's & Non-Hodgkin's



JULY

12-13,

2019

DALLAS, TX



KEY OBJECTIVES:

- Debate the rapidly expanding information on molecular diagnostics, genomic analysis, new molecular targets, and the evolution of care over the next five years of disease
- Discuss management of toxicities, assessment of response and progression, and the influence of microenvironment on resistance and survival
- Debate next generation BTK and PI3K inhibitors and how they compare to first-generation therapy
- Examine how CAR-T cell therapy will change the current treatment landscape
- Discuss the integration of novel therapies, including checkpoint inhibitors, antibody drug conjugates, and bispecific antibodies, into the current treatment paradigm
- Explore new targets for Hodgkin's and non-Hodgkin's lymphoma